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Abstract
Background: Expression of insulin-like growth factor binding protein 5 (IGFBP5) is strongly induced upon
activation of hepatic stellate cells and their transdifferentiation into myofibroblasts in vitro. This was confirmed in
vivo in an animal model of liver fibrosis. Since IGFBP5 has been shown to promote fibrosis in other tissues, the aim
of this study was to investigate its role in the progression of liver fibrosis.
Methods: The effect of IGFBP5 was studied in LX2 cells, a model for partially activated hepatic stellate cells, and in
human primary liver myofibroblasts. IGFBP5 signalling was modulated by the addition of recombinant protein, by
lentiviral overexpression, and by siRNA mediated silencing. Furthermore, the addition of IGF1 and silencing of the
IGF1R was used to investigate the role of the IGF-axis in IGFBP5 mediated effects.
Results: IGFBP5 enhanced the survival of LX2 cells and myofibroblasts via a >50% suppression of apoptosis. This
effect of IGFBP5 was not modulated by the addition of IGF1, nor by silencing of the IGF1R. Additionally, IGFBP5
was able to enhance the expression of established pro-fibrotic markers, such as collagen Ia1, TIMP1 and MMP1.
Conclusion: IGFBP5 enhances the survival of (partially) activated hepatic stellate cells and myofibroblasts by
lowering apoptosis via an IGF1-independent mechanism, and enhances the expression of profibrotic genes. Its
lowered expression may, therefore, reduce the progression of liver fibrosis.
Background
The extensive accumulation of extracellular matrix
(ECM) produced by activated hepatic stellate cells
(HSC), which normally reside in the space of Disse as
the major vitamin A storage site, is a hallmark of liver
fibrosis [1,2]. Liver damage induces HSC activation and,
upon repeated and/or chronic injury, they transdiffer-
entiate into myofibroblast-like cells [1,3]. These cells
migrate to the damaged regions of the liver [4-6] where
they play a central role in the pathogenic deposition of
ECM [7,8].
In order to identify novel therapeutic targets, we used
gene expression profiling at different stages of the
pathogenic transdifferentiation of HSC [9]. One of the
factors found to be upregulated upon HSC activation
and further enhanced upon transdifferentiation into
myofibroblasts was IGFBP5 (insulin-like growth factor
binding protein 5). This strong induction of IGFBP5
expression was confirmed during the development of
liver fibrosis in the Mdr2
-/- mice, a well established ani-
mal model of liver fibrosis [10]. Expression of IGFBP5
in HSC has been reported to be enhanced by insulin-
like growth factor 1 (IGF1) via a post-translational
mechanism, while its novel synthesis was decreased by
TGFb1 (transforming growth factor beta 1) [11].
IGFBP5 is a member the IGFBPs that bind IGF1
[12-14]. IGF1 is mainly synthesized by the liver and gets
secreted into the circulation bound to IGFBPs, which
prolong its half-life and, by modulating its interaction
with the IGF1 receptor (IGF1R), control its biological
activity [12,15,16]. In advanced liver fibrosis, the IGF1
axis is severely impaired mostly due to a reduced num-
ber of healthy IGF1 producing hepatocytes [17]. The
decrease in IGF1 signalling seems to provide a pro-
fibrotic environment, since the progression of liver
fibrosis could be delayed by IGF1 administration [18,19].
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face receptor IGF1R [20], its increased expression in
activated HSC and myofibroblasts may reduce IGF1 sig-
nalling and, thus, promote liver fibrosis. In contrast, in
another study IGF1 has been reported to exert pro-
fibrotic activity [21]. In that case the inhibition of IGF1
signalling by IGFBP5 would impair the pathogenesis of
liver fibrosis.
In lung and skin, IGFBP5 has also been shown to
induce fibrosis upon epithelial injury [13,22,23]. Induc-
tion of IGFBP5 expression initiated the activation and
transdifferentiation of resident fibroblasts into myofibro-
blasts, causing increased ECM production and deposi-
tion in these tissues. Moreover, it seemed to cause
cellular senescence and epithelial-mesenchymal transi-
tion [24].
The aim of this study was to investigate the role of
IGFBP5 in liver fibrosis by employing both gain and loss
of function approaches. We focused on the effect of
IGFBP5 on HSC, using the human LX2 cell line [25],
which recapitulates many features of the activated HSC
phenotype. In addition, to see if IGFBP5 could play a
role in more advanced stages of fibrosis, we analysed its
effect on human primary liver myofibroblasts.
Materials and methods
Cell culturing
LX2 cells (kindly provided by Prof. dr. S. Friedman) and
human myofibroblasts (obtained as described [9]) were
cultured in Dulbecco’s modified Eagle’s medium (Lonza,
Verviers, Belgium), supplemented with 10% fetal calf
serum (FCS), 1 mmol/l L-glutamine, 100 IU/ml penicil-
lin and streptomycin. Human recombinant IGFBP5 and
IGF1 (rIGFBP5 and rIGF1; Gro-Pep, Reutlingen, Ger-
many) were added in concentration 0.1 ng/μl [26] and 1
ng/μl, respectively, at 24 and 45 h of cell culturing. The
cells were used for additional assays 3 h after the last
protein additions.
In order to induce apoptosis, the cells were serum
deprived for 48 h. For drug induced apoptosis, the cells
grown in 10% FCS were incubated with 0.5 μM glio-
toxin (Alexis Biochemicals, Lausen, Switzerland) for 3 h.
This dose induced caspase activity sixfold 3 h after glio-
toxin administration (data not shown).
Lentiviral transduction
A lentiviral vector encoding human IGFBP5 behind the
constitutive PGK promoter was generated using the self-
inactivating cppt-PGKiresGFP-PRE vector [27]. Sequen-
cing was performed to exclude mutations.
siRNA mediated silencing
IGFBP5, IGF1R and negative control small interfering
RNAs (siRNAs) were purchased from Invitrogen (Breda,
Netherlands). siRNA was introduced to the cells using
Lipofectamine 2000 (Invitrogen, Breda, Netherland) in
Optimem (Gibco, Invitrogen, Paisley, UK), according to
the manufacturer’s instructions. For the downstream
applications siRNA transfected cells were grown in 10%
FCS and used 48 h after transfection. When apoptosis
was induced by serum starvation, the cells were first
grown o/n (16 h) in serum containing medium, which
was then replaced for 48 h by serum depleted medium.
Cell viability test
Cell Proliferation Reagent WST-1 (Roche Applied
Science, Mannheim, Germany) was added (1/10th of the
culture volume) to cells grown in 96-well plates. Absor-
bance was measured at 450 nm (reference at 630 nm)
immediately and after 1 h of incubation at 37°C.
Bromo-2’-deoxy-uridine (BrdU) assay
BrdU assay (Roche applied Science, Penzberg, Germany)
was performed according to the manufacturer’sp r o t o -
col. The cells grown in 96 well plates were incubated
with BrdU during the last 16 h of culturing.
Apoptosis assay
The Apo-One homogeneous Caspase 3/7 assay (Pro-
mega, Medison, WI, USA) was performed according to
the manufacturer’s protocol. The Apo-One Caspase 3/7
reagent was added in a 1:1 ratio with medium and fluor-
escence was measured using Novostar plate reader at
521 nm.
Reverse transcription and quantitative polymerase chain
reaction (qPCR)
Total RNA was isolated using Trizol (Invitrogen, Breda,
The Netherlands). RNA concentration was determined
spectrophotometrically and the integrity was checked by
gel electrophoreses. cDNA was synthesized using an
oligo-dT primer and Superscript III (Invitrogen, Breda,
The Netherlands). qPCR was performed on a LightCy-
cler using FastStart DNA Master Plus SYBR Green I
(Roche, Mannheim, Germany). The relative expression
levels were calculated using the LinReg program [28]
and for each sample normalized by the expression of
housekeeping gene 36B4 (acidic ribosomal phosphopro-
tein P0). Primer sequences are shown in Table 1.
Western blot analysis
Cell extracts were analysed by Western blotting as
described [29]. We used antisera against IGFBP5 (1:250;
Abcam, Cambridge, UK), IGF1R (1:200; Santa Cruz Bio-
technology, CA, USA), poly (ADP-ribose) polymerase
(PARP; 1:100; Promega, Madison, USA) and b-actine
(1:3000; Sigma, St Louis, USA). Goat anti-mouse (1:2500;
Bio-Rad Laboratories, Veenendaal, The Netherlands) and
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(1:5000; Santa Cruz Biotechnology, CA, USA) were used
as secondary antibodies. Chemiluminescence was quanti-
fied on the Lumi-Imager F1 using CDP-Star (Roche, Man-
nheim, Germany). Amido-black staining and b-actine
immuno-blot verified similar protein loading.
Statistical analysis
All cell culturing experiments were performed in quad-
ruplo, and were repeated at least three times. In order
to assess the significance of the data, ANOVA analysis
and Student’s t test were employed. The error bars in
the figures represent the standard deviation. Significance
threshold was set to P < 0.05 (denoted by the asterisks
in all the Figures).
Results
IGFBP5 expression in LX2 cells
In human HSC in vitro, IGFBP5 expression is enhanced
twofold upon activation and 200-fold upon transdifferen-
tiation into myofibroblasts [9]. LX2 cells also express
IGFBP5 (Table 2). The 30% higher expression in these
cells compared to resting HSC confirms reports demon-
strating that it is a model for partially activated HSC [25].
In order to investigate a potential role of IGFBP5 in
liver fibrosis, we developed methods to modulate its
expression in LX2 cells. The endogenous expression of
IGFBP5 mRNA was doubled using lentiviral transduc-
tion (Figure 1A). This resulted in a 2.5-fold increase in
protein levels (Figure 1B). Transfection with IGFBP5
siRNA reduced IGFBP5 mRNA 80% and led to complete
absence of detectable IGFBP5 signal on a Western blot
(Figure 1C and 1D, respectively).
IGFBP5 enhances survival of LX2 cells
Several studies have shown that IGFBP5 can affect cell
survival [30-33]. We therefore compared the viability of
control LX2 cells with cells over-expressing IGFBP5.
When grown with 10% FCS, cell growth did not differ
(data not shown). However, upon culturing in serum
free medium for 48 h, a WST assay (for cell viability)
indicated 100% higher viability of the transduced cells
(Figure 2A). The similar 60% increase in viability seen
upon addition of recombinant IGFBP5 (rIGFBP5)
confirmed the effect of IGFBP5 on LX2 survival
(Figure 2B). In serum free medium, the siRNA mediated
reduction of IGFBP5 expression resulted in a >40%
decrease in cell viability. This reduction in viability was
prevented by the addition of rIGFBP5 to the silenced
cells (Figure 2C).
In order to investigate if IGFBP5 affected proliferation,
we studied its effect on the BrdU incorporation. In the
cells grown in serum depleted medium the addition of
0.1 ng/μl rIGFBP5 at 24 h and 45 h of culturing did not
effect the incorporation of BrdU (Figure 2D). This indi-
cates that IGFBP5 does not enhance LX2 cell
proliferation.
Impact of IGFBP5 on apoptosis in LX2cells
In order to investigate if the effect of IGFBP5 on viabi-
lity was caused by decreased apoptosis, we determined
Table 1 Primers sequences used in quantitative polymerase chain reaction.
Gene Symbol Primers (5’®3’)
Insulin-like growth factor binding protein 5 IGFBP5 F: GTCACTCCCCAGAGAAGCTG
R: CCCCTGCTTAGATTGCCATA
Insulin-like growth factor 1 receptor IGF1R F: GGTTGAGGTGAGAGGTTTGC
R: CAAATTGGCCATGTTATTACCTT
Acidic ribosomal phosphoprotein P0 36B4 F: AGGCGTCCTCGTGGAAGTGA
R: GCGGATCTGCTGCATCTGCT
Matrix metallopeptidase 1 MMP1 F: AGCTAGCTCAGGATGACATTGATG
R: CTCCCCGAATCGTAGTTATAGCAT
TIMP metallopeptidase inhibitor 1 TIMP1 F: CACCCACAGACGGCCTTCT
R: TCTGGTGTCCCCACGAACTT
Collagen, type I, alpha 1 COL1A1 F: GGCGGCCAGGGCTCCGAC
R: AATTCCTGGTCTGGGGCACC
B-cell CLL/lymphoma 2 BCL2 F: GTTGGTGGGGTCATGTGTGTGGAGAG
R: TAGCTGATTCGACGTTTTGCCTGA
Table 2 Relative gene expression of insulin-like growth
factor 1 (IGF1) and insulin-like growth factor binding
protein 5 (IGFBP5) in LX2 cells, activated hepatic stellate
cells (HSC) and myofibroblasts given as fold changes of
basal expression in freshly isolated human HSC.
LX2 cells HSC Activated HSC Myofibroblasts
IGFBP5 1.3 1 2.3 236
IGF1 0.7 1 1.2 0.3
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Page 3 of 13Figure 1 Modulation of IGFBP5 expression in LX2 cells.( A )IGFBP5 mRNA levels in control cells (LX2) and in cells with lentiviral
overexpression of IGFBP5 (LX2(BP5)). RNA levels normalized to 36B4 are shown as a percentage of control cells. (B) IGFBP5 protein levels in
control (LX2) and transduced (LX2(BP5)) cells as demonstrated on a Western blot (upper panel) and quantified using the LumiImager (lower
panel). (C) Silencing of IGFBP5 expression. Cells were transfected with small interfering (si) RNA for IGFBP5 (siBP5) or with a control siRNA (siCtrl).
RNA was isolated 48 h later and IGFBP5 mRNA levels were quantified, normalized to 36B4 and given as a percentage of control cells. (D) Proteins
were isolated from the cells and the medium 48 h after small interfering RNA (sRNA) transfection. The presence of IGFBP5 protein was visualized
by Western blotting in LX2 and LX2(BP5) cells transfected with control siRNA (siCtrl) and IGFBP5 siRNA (siBP5) and in medium obtained from
transfected LX2(BP5). The results are given as a percentage of the control cells. The error bars represent standard deviations, with asterisks
denoting significant difference (P < 0.05).
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tion of rIGFBP5 to LX2 cells cultured in serum free
medium did reduce the caspase activity by 40% (Figure
3A). In order to substantiate this protective effect, we
also tested it in a model of drug induced apoptosis by
gliotoxin administration [34]. The addition of rIGFBP5
3 h prior to the addition of 0.5 μMo fg l i o t o x i nr e s u l t e d
in a significant (40%) lowering of caspase activity (Figure
3B). In order to investigate if lowering of IGFBP5 would
increase apoptosis, we studied the effect of siRNA
mediated silencing on its expression. Compared to con-
trol-siRNA transfected cells, the caspase activity in
silenced cells was increased by 30%. This increase was
seen when apoptosis was induced both by serum starva-
tion and gliotoxin. Administration of rIGFBP5 reduced
caspase activity in silenced cells to a level significantly
l o v e rt h a nt h a ti nc o n t r o lc e l l s( F i g u r e3 Ca n d3 D ,
respectively). The increase in apoptosis in silenced cells
was further confirmed by Western blot analysis, which
demonstrated a 150% increase of poly (ADP-ribose)
polymerase (PARP) protein expression in silenced com-
pared to control cells (Figure 3E).
Altogether, these data indicate that IGFBP5 enhances
the survival of this model for partially activated HSC by
arresting apoptosis.
IGFBP5 also enhances survival of human myofibroblasts
Activated HSC transdifferentiate into myofibroblasts in
advanced stages of liver fibrosis. This transdifferentiation
results in a further induction of IGFBP5 expression [9].
Given the effects on LX2 cells, IGFBP5 may also affect
the survival of liver myofibroblasts. In order to investi-
gate this, we performed siRNA mediated silencing of
IGFBP5 expression in primary human myofibroblasts
(Figure 4A). Forty-eight hours after transfection, IGFBP5
mRNA levels in primary myofibroblasts were decreased
by 60%. Although the silencing was not as effective as
that in LX2 cells, it did cause a small, but significant,
decrease in survival, which could be prevented by the
addition of both rIGF1 and rIGFBP5 (Figure 4B). As in
LX2 cells, this decrease in survival was due to an
increase in caspase activity that could be avoided by the
addition of rIGF1 and rIGFBP5 (Figure 4C). Thus,
IGFBP5 also increases the survival of human liver myofi-
broblasts by reducing apoptosis.
Involvement of BCL2
In order to investigate the mechanism involved in the
anti-apoptotic effect of IGFBP5 we studied its effect on
the expression of several pro- and anti-apoptotic genes.
The enhanced expression of IGFBP5 in transduced cells
Figure 2 IGFBP5 increases survival of LX2 cells. (A) The viability of IGFBP5 overexpressing (LX2(BP5)) and control cells (LX2) cultured in serum-
free medium for 48 h was measured using WST. (B) The viability of LX2 cells cultured in serum-free medium for 48 h was determined using
WST. At t = 24 and 45 h, recombinant IGFBP5 was added (rBP5). (C) LX2 cells were transfected with small interfering control (siCtrl) or IGFBP5
siRNA (siBP5). At 16 h after transfection the medium was replaced by serum-free medium and 48 h later the viability of the cells was measured
using WST. rIGFBP5 was added at t = 24 and 45 h of serum-free culturing (siBP5+rBP5). (D) Bromo-2’-deoxy-uridine (BrdU) incorporation was
used to determine the proliferation of LX2 cells cultured in serum-free medium for 48 h. rIGFBP5 was added at t = 24 and 45 h (rBP5). BrdU was
added at t = 32 h. The results are shown as percentage of the control cells.
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phoma 2 (BCL2) mRNA levels (Figure 5). Also, the addi-
tion of rIGFBP5 to IGFBP5 silenced LX2 cells resulted
in a clear increase in BCL2 expression. The lack of effect
of IGFBP5 silencing on BCL2 expression is unexpected
and seems to suggest that, in presence of low levels of
IGFBP5, other factors do determine (basal) BCL2
expression. BCL2 mRNA induction by high IGFBP5
levels seems to suggest that it could play a role in the
anti-apoptotic effect of IGFBP5, but additional studies
such as BCL2 silencing are needed in order to establish
this possibility.
Increased cell survival by IGFBP5 seems independent of
IGF1
IGFBP5 binds IGF1 with high affinity. Therefore, its
protective role in LX2 cells and myofibroblasts could be
due to modulation of the pro-survival effects of IGF1
signalling [20,35]. In order to investigate if IGFBP5
exerts its action via IGF1, we also determined the effect
of IGF1 on LX2 cells viability. As with IGFBP5, the
addition of IGF1 induced a 70% increase in survival of
LX2 cells (Figure 6A), and lowering of apoptosis by 40%
(Figure 6B). In order to investigate if IGF1 effect is
modulated by IGFBP5, we studied the effect of the two
Figure 3 IGFBP5 impact on apoptosis in LX2 cells. (A) LX2 cells were cultured in serum-free medium for 48 h. Recombinant IGFBP5 (rBP5)
was added at 24 h and 45 h and, at 48 h, a Caspase 3/7 assay was performed. (B) Cells grown in 10% fetal calf serum were treated with rBP5 as
above, with the addition of 0.5 μM gliotoxin after 45 h. (C) LX2 cells were transfected with small interfering control (siCtrl) or IGFBP5 siRNA
(siBP5). Sixteen hours after transfection, the medium was replaced by serum-free medium and cells were cultured for additional 48 h before
performing the caspase assay. To siIGFBP5 transfected cells, recombinant IGFBP5 was added at t = 24 h and 45 h (siBP5+rBP5). (D) To cells
treated with si- and r-BP5 as in C, 0.5 μM gliotoxin was added 3 h before performing the caspase assay. All results are shown as a percentage of
the control cells. (E) Apoptosis was induced in LX2 cells transfected with control siRNA (siCtrl) or IGFBP5 siRNA (siBP5) by the addition of 0.5 uM
gliotoxin at t = 45 h. Proteins were isolated at 48 h and Western blotting was performed for poly(ASP-ribose) polymerase detection (left panel).
Quantification is shown in the right panel. b-actin was used as a loading control.
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Page 6 of 13Figure 4 In human myofibroblasts IGFBP5 silencing decreases survival and promotes apoptosis. (A) Primary human myofibroblasts were
transfected with small interfering (si) RNA for IGFBP5 (siBP5) or with a control siRNA (siCtrl). At 16 h after transfection the medium was replaced
by serum-free medium. Cells were cultured for an additional 48 h. Then RNA was isolated and IGFBP5 mRNA level determined by quantitative
polymerase chain reaction and normalized with 36B4. (B) Recombinant IGFBP5 (rBP5), IGF1 (rIGF1), or both (rIGF1+ rBP5), where added at t =2 4
h and 45 h, after replacing the medium, to siBP-5 transfected cells. At 48 h the WST assay was performed. (C) To cells treated as above but
grown in 10% fetal calf serum, 0,5 μM gliotoxin was added at 45 h. Caspase 3/7 assay was performed at 48 h. Results are given as a percentage
of control cells.
Sokolović et al. Fibrogenesis & Tissue Repair 2010, 3:3
http://www.fibrogenesis.com/content/3/1/3
Page 7 of 13factors added together. The response in viability and
apoptosis were similar when IGF1 and IGFBP5 were
added, alone or in combination (Figure 6A and 6B).
However, in contrast to IGFBP5, IGF1 was able to
enhance proliferation of LX2 cells for about 40% (Figure
6C), indicating that the two factors exert different effects
on LX2 cells.
In order to establish a possible IGF1-independent
effect of IGFBP5, we chose to silence IGF1R, the recep-
tor that mediates IGF1 signalling. Transfection of LX2
cells with siRNA for IGF1R resulted in a 90% drop of
IGF1R protein expression after 48 h (Figure 6D). This
large decrease effectively inhibited the pro-survival effect
of IGF1, but not that of IGFBP5 (Figure 6E). The possi-
bility of IGF1-independent action of IGFBP5 was further
confirmed by the addition of rIGFBP5 to IGF1R-silenced
LX2 cells, which caused a decrease in caspase activity,
even to the level below that in the control cells. The
addition of IGF1, on the other hand, was not able to
overcome the effect of IGF1R silencing and its effect on
caspase activity was lacking (Figure 6F). Thus, in con-
trast to IGF1, the effect of IGFBP5 on LX2 cells survival
is not mediated by the IGF1R, suggesting that the effect
it exerts on partly activated stellate cells is not by modu-
lation of IGF1 signalling.
IGFBP5 and fibrotic markers
In tissues such as lung and skin, IGFBP5 was reported
to enhance the expression of established pro-fibrotic
markers, such as aSMA, collagen and fibronectin. As
changed expression of these markers could further
establish the (pro-fibrotic) role of IGFBP5 in liver fibro-
sis, we examined its influence on their expression in
LX2 cells. As shown in Figure 7, overexpression of
IGFBP5 induced the mRNA level of collagen, type I,
alpha 1 (COL1A1) by 70%, tissue inhibitor of metallo-
proteinase (TIMP) metallopeptidase inhibitor 1 (TIMP1)
by 70% and matrix metallopeptidase 1 (MMP1) by 100%
in LX2 cells (Figure 7A-C). Silencing of IGFBP5 reduced
the expression of these genes, which could be recuper-
ated by the addition of recombinant IGFBP5. This indi-
cates that IGFBP5 may not only enhance fibrosis by
promoting the survival of activated HSC and myofibro-
blasts, but also by stimulating the expression of pro-
fibrotic genes in these cells.
Discussion
We have previously shown that IGFBP5 expression was
strongly upregulated during HSC transdifferentiation in
vitro and during development of liver fibrosis in vivo
[9]. The aim of this study was to scrutinize the role of
IGFBP5 in (partially) activated and transdifferentiated
hepatic stellate cells.
IGFBP5 expression is increased in fibrotic lung, skin
and liver [9,10,22,23]. The effects of IGFBP5 depend on
cell type and tissue. For instance, in the process of
mammary gland involution, IGFBP5 promotes apoptosis
of epithelial cells in vivo and in vitro [36-39]. In con-
trast, an anti-apoptotic role of IGFBP5 has been
reported, for instance, in myogenesis, in breast cancer
cells grown in vitro, and in gingival epithelial cells
[40-43].
Figure 5 IGFBP5 influences BCL2 expression. LX2 cells were transfected with control small interfering RNA (siCtrl) or IGFBP5 siRNA (siBP5).
Sixteen hours after transfection the medium was replaced by serum-free medium. Recombinant IGFBP5 was added at t = 24 h and 45 h, after
replacing the medium, to siIGFBP5 transfected cells (siBP5+rBP5). After 48 h RNA was isolated from control (siCtrl), silenced (siBP5), silenced
treated with rIGFBP5 (siBP5+rBP5) and LX2 cells overexpression IGFBP5 (LX2(BP5)) and used for quantitative polymerase chain reaction in order
to determine BCL2 mRNA. The BCL2 mRNA levels were normalized to 36B4 and given as a percentage of control cells.
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activated HSC that play a pivotal role in the initiation
and perpetuation of this pathological process [44]. Since
IGFBP5 is induced in these cells upon activation and
can promote survival, it may play a role in increasing
the numbers of these activated cells seen in fibrotic
liver. In order to study the effects of IGFBP5 in vitro,
we used primary human myofibroblasts and LX2 cells,
an established human model cell line for partially acti-
vated HSC [45-47]. The expression of IGFBP5 in LX2
cells was 30% higher than in quiescent normal HSC. For
comparison, in cultured (that is, partially activated)
HSC, IGFBP5 expression was doubled, while in hepatic
myofibroblasts expression went up more than 200-fold.
We used lentiviral transduction of LX2 cells to enhance
the IGFBP5 expression to the levels seen in activated
HSC. Upon serum depletion, both IGFBP5 over-
expression and the addition of rIGFBP5 promoted the
survival of LX2 cells by lowering the apoptosis. This
suggests that the increased IGFBP5 expression could
play a role in the reduction of apoptosis seen in acti-
vated HSC in the fibrotic liver. In accordance, lowered
IGFBP5 expression by RNA silencing decreased the via-
bility of LX2 cells. IGFBP5 silencing also decreased sur-
vival in human primary liver myofibroblasts. In both cell
types this was due to increased apoptosis, demonstrating
that IGFBP5 functions as an anti-apoptotic, pro-survival
factor in these two pro-fibrotic cell types. Two recent
studies reported a high expression of IGFBP5 in hepato-
cellular carcinoma (HCC) and intra-hepatic cholangio-
carcinoma (CC), suggesting that it has a similar role in
vivo by promoting the survival of cancer cells [48,49].
We demonstrated that IGFBP5 expression strongly
increased during development of liver fibrosis in Mdr2
-/-
Figure 6 Cell survival by IGFBP5 is not affected by IGF1 or mediated by IGF1R. (A) LX2 cells were transfected with IGFBP5 small interfering
RNA (siBP5). Sixteen hours after transfection the medium was replaced by serum-free medium for 48 h and then the viability was determined
by performing a WST assay. Recombinant IGFBP5 (rBP5), IGF1 (rIGF1), or both (rIGF1+ rBP5), were added at 24 hand 45 h. (B) To cells treated as
above, but cultured in 10% fetal calf serum, 0.5 μM gliotoxin was added at 45 h followed by a Caspase 3/7 assay 3 h later. (C) LX2 cells were
cultured in serum-free medium for 48 h. rIGF1 was added in different concentrations at 24 h and 45 h, bromo-2’-deoxy-uridine (BrdU) was
added at 32 h. Cells were lysed 16 h later (at 48 h) and assayed for BrdU incorporation. (D) LX2 cells were transfected with control (siCtrl) or
siRNA for IGF1R (siIGF1R). Sixteen hours after transfection the medium was replaced by serum-free medium and cells were cultured for additional
48 h. The cells were then lysed and used for Western blot analysis in order to detect IGF1R. (E) Cells were transfected and cultured as in D. rIGF1
or rIGFBP5 (rBP5) was added at t = 24 h and 45 h after replacing medium. After 48 h a WST assay was performed. (F) 0.5 μM gliotoxin was
added at 45 h, after replacing the medium. Caspase activity was measured 3 h later. All results are given as a percentage control cells.
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Page 9 of 13Figure 7 IGFBP5 influences the expression of genes involved in fibrogenesis. LX2 cells were transfected with small interfering control
(siCtrl) or IGFBP5 siRNA (siBP5). Sixteen hours after transfection, medium was replaced by serum-free medium. Recombinant IGFBP5 (rIGFBP5) was
added at 24 h and 45 h, after replacing the medium, to siIGFBP5 transfected cells (siBP5+rBP5). After 48 h of culturing on serum-free medium
RNA was isolated from control, transfected and transfected treated with rIGFBP5. For comparison, RNA was isolated from LX2 cells
overexpressing IGFBP5 cultured in serum-free medium (LX2(BP5)). Collagen 1a1 (A),TIMP1 (B) and MMP1 (C) mRNA levels were measured with
quantitative polymerase chain reaction, normalized to 36B4 and given as a percentage of control cells.
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Page 10 of 13mice [9]. This model of liver fibrosis not only sponta-
neously develops portal fibrosis, but is also prone to
HCC formation [50,51]. The presence of IGFBP5 in this
animal model and in patients with HCC or CC suggests
that, in addition to a role in the pathogenesis of liver
fibrosis, IGFBP5 may also contribute to tumour forma-
tion. Lowering IGFBP5 expression may, therefore, not
only impair the development of liver fibrosis but also
reduce the risk of tumour formation.
The role of IGFBP5 in IGF1 signalling is well estab-
lished. IGFBP5 binds IGF1 with high affinity and pro-
tects it from rapid degradation [20] but, at the same
time, prevents induction of the IGF1R and thereby inhi-
bits pro-survival signalling by IGF1. The observed effects
of IGFBP5 may therefore be due to its role in IGF1 sig-
nalling - that is to its disturbance of the IGF1 axis
observed in liver fibrosis [19]. Our in vitro studies show,
however, that, in contrast to IGFBP5, IGF1 increases
proliferation of LX2 cells. Moreover, no effect of IGF1
on IGFBP5 action, nor of IGFBP5 on IGF1 signalling,
was detected. Therefore, it seems that the two factors
exert their effect on LX2 cells via different routes. In
line with this, silencing of IGF1R resulted in loss of the
pro-survival effects of IGF1 but did not interfere with
the pro-survival effects of IGFBP5. This strongly
supports the notion that IGFBP5 promotes survival of
activated HSC by lowering apoptosis in an IGF1-inde-
pendent manner. Several mechanisms, such as activation
of TGFb1, modulation of the coagulation cascade and
integrin activation may be involved in the IGF1-inde-
pendent effect of IGFBP5 [52-54]. In addition, the exis-
tence of an IGFBP5 receptor has been proposed to
explain the IGF1-independent actions of IGFBP5
[53,54].
The finding that IGFBP5 promoted survival without
inducing proliferation suggests that it may induce cellu-
lar senescence. Overexpression of IGFBP5 is shown to
induce senescence in HUVEC cells by induction of the
tumour suppressor p53 [26]. The induction of senes-
cence plays a promoting role in the development of pul-
monary fibrosis [24]. On the other hand, senescence in
activated HSC was associated with impediment of liver
fibrosis [55], leaving the role of IGFBP5 in the develop-
ment of senescence in liver fibrogenesis opened for
further inquiries. Additionally, adenovirally mediated
overexpression of IGFBP5 induced the expression pro-
fibrotic genes and ECM deposition in lung and skin
[22,23]. We showed that IGFBP5 also enhanced the
expression of genes directly involved in liver fibrogenesis
such as collagen1a1, TIMP1 and MMP1 in LX2 cells. Its
effect on these pro-fibrotic genes in a model for acti-
vated HSC indicates that IGFBP5 may also have a direct
effect on the ECM deposition in liver fibrosis. Increase
of both TIMP1 and MMP1 expression, and thus
exertion of both fibrotic and matrix-degrading effects,
could be seen in the light of a necessity to establish a
balance between matrix deposition and restructuring
during the process of fibrogenesis. However, since our
data only demonstrate changes on the mRNA level, it
seems possible that the changes in the expression of
these opposing factors may not have occurred on the
protein level due to posttranscriptional and posttransla-
tional modifications.
In conclusion, our data show that IGFBP5 improves
the survival of (partially) activated HSC and liver myofi-
broblasts by lowering the level of apoptosis via an IGF1-
independent mechanism. In addition, IGFBP5 increases
the expression of genes involved in ECM deposition.
Accordingly, lowering expression of this apparently pro-
fibrotic factor may impair the progression of liver
fibrosis.
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